Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped up prior to trading on Tuesday . The stock had previously closed at $36.18, but opened at $39.27. Nanobiotix shares last traded at $39.7310, with a volume of 23,368 shares traded.

Wall Street Analyst Weigh In

NBTX has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Leerink Partners lifted their target price on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. Finally, UBS Group lifted their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Nanobiotix currently has a consensus rating of “Moderate Buy” and an average target price of $37.33.

Nanobiotix Trading Up 7.5%

The firm’s 50-day moving average is $37.61 and its two-hundred day moving average is $34.21.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its holdings in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares in the last quarter. Marshall Wace LLP acquired a new position in Nanobiotix during the fourth quarter worth $220,000. Finally, Millennium Management LLC bought a new position in Nanobiotix during the fourth quarter valued at about $390,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.